ChromaDex Stock (NASDAQ:CDXC), Trade Ideas

ChromaDex

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAON

ADAP

AGRX

AKYA

ALLK

ALTO

APPH

ARQQ

ARVL

ATHX

ATIP

ATRO

AVCO

BRMK

CDXC

CGTX

CLAR

COIN

CTIC

DBGI

DOCN

EHTH

EOSE

FGEN

FIVN

FSRD

GAIA

GRPN

GRWG

GSUN

HAIN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HOOD

HUDI

ICCM

LITE

LPSN

LPTX

LTRPA

LYFT

LYLT

MAPS

METC

MLNK

MPLN

MRNS

MSTR

NCLH

NCMI

NRBO

NSTG

OABI

OCUL

OCUP

ONCS

ONCY

OPRT

PKBO

PLNT

PNTG

PRGO

PRTY

RETA

ROVR

SEDG

SIBN

SKYT

SLNA

SPWR

TASK

TCMD

TRIP

TRUE

TTWO

UFAB

VORB

VRTV

XELA

XXII

YMAB

Gainers


	Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.


Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday

Intraday Update

Lordstown Motors Corp. - Class A Common Stock

RIDE

TNYA

TWOU

Gainers


	IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare &amp; Medicaid Services for the ProSense breast cancer cryoablation procedures.


Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday&#39;s Mid-Day Session

Long Ideas

Insider Trades

CMRX

TCON

RVPH

The Dow Jones jumped by more than 750 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying

ChromaDex Corp

ChromaDex Announces That Its Flagship Product, Tru Niagen Is Now Available At Sprouts Farmers Market, Marking Its Inaugural Major Grocery Debut

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $4.25 to $6.

Price Target

Analyst Ratings

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6

<h3>Gainers</h3>
<ul>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 29.0% to $1.29. The company's market cap stands at $141.3 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 27.91% to $3.07. The company's market cap stands at $231.1 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock moved upwards by 24.0% to $6.2. The market value of their outstanding shares is at $59.5 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock increased by 23.04% to $2.35. The company's market cap stands at $68.8 million. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock rose 21.08% to $1.55. The company's market cap stands at $14.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 33.0% to $19.3 during Monday's regular session. The market value of their outstanding shares is at $23.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares declined by 27.6% to $3.62. The market value of their outstanding shares is at $70.7 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares decreased by 25.28% to $4.14. The market value of their outstanding shares is at $15.5 million. The company's, Q4 earnings came out today. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares fell 18.34% to $7.59. The market value of their outstanding shares is at $5.7 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock declined by 17.67% to $25.75. The company's market cap stands at $1.0 billion. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 17.28% to $2.27. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCY

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

CRGX

ELTX

FRES

IMRX

MEDS

MTEM

TTNP

12 Health Care Stocks Moving In Monday's Intraday Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $5 to $6.

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6

Guidance

ChromaDex Expects Trajectory Of 2024 Revenue Growth To Continue, Projecting Higher Rate Of Revenue Growth Than Prior Year Growth Of 16%

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by 103.33 percent. This is a 105 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $21.20 million which beat the analyst consensus estimate of $20.98 million by 1.03 percent. This is a 0.95 percent increase over sales of $21.00 million the same period last year.

Earnings

ChromaDex Q4 EPS $0.00 Beats $(0.03) Estimate, Sales $21.20M Beat $20.98M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
&bull; Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion.
&bull; JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $42.16 billion.
&bull; Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $326.63 million.
&bull; Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report earnings for its fourth quarter.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $2.27 billion.
&bull; Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $86.80 million.
&bull; VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $22.43 million.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is expected to report quarterly earnings at $2.83 per share on revenue of $1.43 billion.
&bull; Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.12 billion.
&bull; WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is likely to report quarterly loss at $0.23 per share on revenue of $19.86 million.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is projected to report earnings for its fourth quarter.
&bull; iShares $ Short Duration Corp Bond UCITS ETF USD (Dist) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDIG#NASDAQ">SDIG</a>) is projected to report quarterly loss at $0.98 per share on revenue of $22.21 million.
&bull; InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $1.63 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $658.50 million.
&bull; Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $37.71 million.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is projected to report quarterly loss at $0.23 per share on revenue of $180 thousand.
&bull; Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $43.55 million.
&bull; Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is expected to report quarterly loss at $0.07 per share on revenue of $126.13 million.
&bull; Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $20.47 million.
&bull; NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is estimated to report quarterly loss at $4.16 per share on revenue of $283.44 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $2.44 billion.
&bull; EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $44.03 million.
&bull; Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is estimated to report quarterly loss at $2.01 per share on revenue of $55.25 million.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.01 per share on revenue of $8.42 million.
&bull; Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $1.75 million.
&bull; European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $54.08 million.
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $579.42 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $7.87 billion.
&bull; Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $182.37 million.
&bull; Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter.
&bull; Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) is estimated to report quarterly earnings at $0.54 per share on revenue of $46.42 million.
&bull; Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) is expected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $144.29 million.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $261.00 million.
&bull; Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $1.27 per share on revenue of $340 thousand.
&bull; Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.32 billion.
&bull; Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $121.92 million.
&bull; Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $440.69 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $234.91 million.
&bull; Victoria&#39;s Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $2.09 billion.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is expected to report quarterly loss at $0.23 per share on revenue of $61.45 million.
&bull; KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $212.97 million.
&bull; Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly loss at $0.16 per share on revenue of $59.49 million.
&bull; GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $43.95 million.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $174.28 million.
&bull; IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is projected to report earnings for its second quarter.
&bull; FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is projected to report earnings for its fourth quarter.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $12.00 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is projected to report quarterly loss at $0.07 per share on revenue of $54.53 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is estimated to report earnings for its fourth quarter.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $76.22 million.
&bull; Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is likely to report quarterly loss at $0.09 per share on revenue of $421.19 million.
&bull; Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $280 thousand.
&bull; Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is expected to report quarterly loss at $0.12 per share on revenue of $70 thousand.
&bull; HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $339.52 million.
&bull; BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $123.75 million.
&bull; MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $18.14 million.
&bull; NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is estimated to report earnings for its fourth quarter.
&bull; Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $260.16 million.
&bull; Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $43.57 million.
&bull; OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $58.26 million.
&bull; Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $84.14 million.
&bull; SilverCrest Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SILV#AMEX">SILV</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $7.93 million.
&bull; comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $97.69 million.
&bull; Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.00 million.
&bull; Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is projected to report earnings for its third quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $20.98 million.
&bull; Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is projected to report earnings for its fourth quarter.
&bull; Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter.
&bull; OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.73 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $40.28 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is projected to report earnings for its fourth quarter.
&bull; Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) is projected to report quarterly loss at $0.20 per share on revenue of $10.00 million.
&bull; Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is projected to report quarterly loss at $0.08 per share on revenue of $63.22 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $100.24 million.
&bull; TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $33.13 million.
&bull; CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $96.49 million.
&bull; Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $222.52 million.
&bull; Cyber Hornet S&amp;P 500 and Bitcoin 75/25 Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZZZ#NASDAQ">ZZZ</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $247.43 million.
&bull; Ellington Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $2.46 million.
&bull; Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is expected to report quarterly loss at $0.72 per share on revenue of $29.34 million.
&bull; Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $73.40 million.
&bull; Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) is likely to report quarterly loss at $0.03 per share on revenue of $178.56 million.
&bull; Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.30 million.
&bull; Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $437.34 million.
&bull; Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is estimated to report quarterly earnings at $1.60 per share on revenue of $94.75 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is expected to report quarterly loss at $0.43 per share on revenue of $15.45 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEYE

AIRG

AMPY

ARIS

BRCC

BWAY

CMPO

CPSH

CULP

DSGX

EARN

EHAB

EVGO

EWCZ

FRPH

GENI

GENK

GROV

GWRS

HDSN

HIPO

HNST

HTOO

INFN

KEQU

KIDS

KLXE

KMDA

LVLU

MDXH

NEUE

NEXN

NGMS

NSPR

OSPN

PowerShares Insured Municipal Bond Portfolio

REPX

REVG

SCOR

SDIG

SGHC

SILV

SLNG

SOHO

SPIR

TDCX

TLPH

TPVG

TRIN

UNFI

VBNK

VSCO

VSEC

XERS

YEXT

ZYME

Earnings Scheduled For March 6, 2024

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Here's what investors need to know before the announcement.
Analysts estimate that ChromaDex will report an earnings per share (EPS) of $-0.03. 
ChromaDex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 11.25% drop in the share price the next day.
Here's a look at ChromaDex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709654529_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ChromaDex were trading at $1.66 as of March 04. Over the last 52-week period, shares are down 8.74%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CDXC/earnings">To track all earnings releases for ChromaDex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For ChromaDex

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation.
SAN DIEGO, Dec. 12, 2023 /PRNewswire/ -- Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an NAD+ supplement called <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4046427-1&amp;h=791499261&amp;u=https%3A%2F%2Fneurohacker.com%2Fshop%2Fqualia-nad&amp;a=Qualia+NAD%2B">Qualia NAD+</a> that tackles the challenge of boosting NAD+ levels in aging Americans.&#x2A;
A promising pilot study on Qualia NAD+ resulted in 95% of participants rating the experience as "excellent" to "good."&#x2A;
Qualia NAD+'s NR is in the form of Niagen, one of the most efficient NAD+ precursors as it can cross the cell membrane directly, which is created by ChromaDex, a global authority on NAD+ and healthy aging research. As the only successfully FDA-notified form of&nbsp;NR on the market, Niagen represents the highest quality and scientific standards, backed by two Nobel Prize Winners, over 25 human clinical studies, 300+ published studies and is clinically proven to boost NAD+ levels up to 51%.&#x2A;
<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4046427-1&amp;h=255394807&amp;u=https%3A%2F%2Fneurohacker.com%2Fthe-formulator-s-view-of-the-qualia-nad-ingredients&amp;a=Click+here+to+learn+how+Qualia+NAD%2B+can+provide+support+for+optimized+NAD%2B+levels+in+adults+and+boost+your+NAD%2B+levels+up+to+50%25.">Click here to learn how Qualia NAD+ can provide support for optimized NAD+ levels in adults and boost your NAD+ levels up to 50%.</a>
"Created with the highest scientific rigor and quality standards, our patented Niagen NR ingredient is the most efficient precursor available because it can cross the cell membrane directly," states ChromaDex Senior Vice President of Business Development, Jason Campbell. "We look forward to this partnership with Neurohacker Collective as the unique Qualia NAD+ formulation will expand the positive effects of our precious Niagen to more people worldwide."&#x2A;
In the last decade, science has discovered countless links between healthy aging, and maintaining high levels of the molecule NAD+. In humans, NAD+ levels have been shown to decline naturally by up to 65% between age 30 and 70 and due to everyday stressors (overeating, a sedentary lifestyle, excess sun exposure, and others), making NAD+ a contributor to age-related decline
As a result, supplements to support high NAD+ levels now generate over half a billion dollars in annual revenue, with 13% annual market growth projected between 2022 and 2030.
The human body actually makes the NAD+ molecule. It's sometimes called "the aging molecule" due to its many roles in promoting optimal health as we age. This is because NAD+ plays an essential role in vital cellular processes including mitochondrial function, cellular energy production, and DNA repair.&nbsp;
While moderate exercise and calorie restriction can naturally elevate NAD+, leading researchers have identified that supplementation with precursors, or building blocks of NAD+, are perhaps the most direct and potent way to increase levels because precursors readily convert to NAD+ within our cells. Examples include:
<ul>
<li>Niacin</li>
<li>Niacinamide</li>
<li>Nicotinamide riboside or NR (patented as Niagen&#xAE;)</li>
</ul>
What Makes Qualia NAD+ Unique?
Many NAD+ supplements provide one of these NAD+ precursors. However, each person's physiology is slightly different in terms of how efficiently it can convert one NAD+ precursor vs. another.
Qualia NAD+&nbsp;therefore provides all three NAD+ precursors listed above, along with eleven other ingredients shown to support additional aspects of NAD+ production.&#x2A;
Additionally, a promising pilot study on Qualia NAD+ resulted in 95% of participants rating their experience with the formula as "good" to "excellent."&#x2A;
"NAD+ levels have become a key indicator of monitoring how well someone is aging," states Neurohacker Collective CEO James Schmachtenberger.&#x2A;
"Our science team was uniquely equipped to formulate a revolutionary NAD+ product because optimizing NAD+ levels requires the type of complex nutritional science we've specialized in for nearly a decade. Qualia NAD+ provides consumers the type of deeply comprehensive NAD+ support that the market had been lacking."
"We also valued impeccable sourcing for each ingredient we selected. For example, we're honored to partner with ChromaDex to use their patented Niagen NR as it is an ingredient at the forefront of the NAD+ industry-leading in quality and clinical evidence. We used a similar vetting philosophy for every ingredient in the formula."&#x2A;
Some of the most credentialed and respected aging scientists in the world, from Dr. Charles Brenner, one of the world's foremost NAD+ experts, to Dr. Rhonda Patrick, have recently elevated public awareness concerning&nbsp;NAD+ on popular podcasts such as Joe Rogan,Lex Friedman, and Simon Hill.
The gold rush on how to best crack the code of NAD+ production makes the market potential of a formula like Qualia NAD+ potentially category-leading.
"This is our 3rd product that promotes better aging." adds Schmachtenberger. "If we can help millions of people enjoy 20 or 30 extra years of living in prime health, then we're creating the type of transformative changes that inspired us to form as a science team in the first place."&#x2A;
"It's such an exciting time at the frontier of nutritional science right now, and our research is constantly striving to contribute to the forefront of aging science."&#x2A;
Qualia NAD+ became available through <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4046427-1&amp;h=1442088544&amp;u=http%3A%2F%2Fwww.neurohacker.com%2F&amp;a=neurohacker.com">neurohacker.com</a> beginning in early October, with an expanded product launch anticipated in additional channels shortly.

Neurohacker Collective And ChromaDex Partner To Optimize Cellular Health With The Debut Of Qualia NAD+

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chromadex.com%2F&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=ChromaDex+Corp.&amp;index=1&amp;md5=ddfda3def56679f7b5e25a5c042af7ba">ChromaDex Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD). This study was part of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chromadex.com%2Fresearch%2Fcerp%2F&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=ChromaDex+External+Research+Program&amp;index=2&amp;md5=1c117d2b5d9bd919370fa5de8c1d9e1d">ChromaDex External Research Program</a> (CERP&#x2122;), which donated ChromaDex's patented NR ingredient, Niagen&#xAE;, the most efficient and high quality NAD+ precursor, for the advancement of this research.
In a pioneering development for PD treatment, this landmark phase I randomized, double-blind clinical study reported in the peer-reviewed journal <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41467-023-43514-6&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=Nature+Communications&amp;index=3&amp;md5=1c71cd07f031c9656d530f6bf4d18a3a">Nature Communications</a> by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen in Norway, demonstrated that supplementing individuals with PD with high-dose (3,000 mg daily) Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, augmented the NAD+ metabolome, and was associated with a significant clinical improvement. These results build upon previous research led by Dr. Tzoulis (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cell.com%2Faction%2FshowPdf%3Fpii%3DS1550-4131%252822%252900045-6&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=Cell+Metabolism&amp;index=4&amp;md5=63466c239d4c20d6723cc2c682231a8a">Cell Metabolism</a>) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
With several studies demonstrating the safety and tolerability of 2,000mg of Niagen NR, this marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.
"As the world's leading company in NAD+ research and commercialization, ChromaDex is proud to announce this groundbreaking NR-SAFE study from Dr. Tzoulis and his team of researchers that reveals the potential of Niagen NR as a therapy for Parkinson's disease. PD affects more than 10 million people worldwide," noted Rob Fried, CEO of ChromaDex. "This research not only demonstrates the safety and tolerability of high-dose Niagen NR but also highlights its ability to significantly increase NAD+ levels and potentially improve the clinical severity of PD."
PD is a common neurodegenerative disorder largely characterized by progressive impairments in motor function, including tremors, stiffness, slow movement, and poor balance, as well as in non-motor functions, such as abnormal sleep patterns, gastrointestinal dysfunction, and cognitive impairment, or dementia. Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
"Results of this study build on previous research conducted by our lab, demonstrating that oral NR therapy increases NAD+ levels in the brain of individuals with PD and this is associated with ameliorated brain metabolism and mild clinical improvement," commented Prof. Charalampos Tzoulis, Professor of Neurology and Neurogenetics, Director of the K.G Jebsen Center for Translational Research in Parkinson's disease, and Co-Director of the Neuro-SysMed Research Center, University of Bergen and Haukeland University Hospital, Bergen, Norway. "Abnormal energy metabolism due to dysfunction in the mitochondria has been linked to PD and is believed to play a role in the initiation and progression of the disease. Our previous findings have nominated NR as a potential disease-modifying therapy for PD, which will not only target and rectify disease-specific processes, but may also optimize neuronal metabolism and fortify neurons, rendering them more resilient against age-related stress and neurodegeneration. However, to harness the full therapeutic potential of NR, we need to explore higher dose regimens. This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials. As for conclusive proof on the therapeutic potential of NR in PD, we look forward to the results from our year-long NO-PARK phase II/III study on 400 persons with PD, which is already ongoing at our Center, and estimated to conclude by the end of 2024." Public information on the NO-PARK study can be viewed at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fneuro-sysmed.no%2Fdis-clinic-stud%2Fparkinsons-disease%2F&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=neuro-sysmed.no&amp;index=5&amp;md5=302bac2910f304a5c360cab8c8c03325">neuro-sysmed.no</a> and at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03568968&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=6&amp;md5=5917ddafb7cb9d85f6aa842110bf3823">www.clinicaltrials.gov</a>. Notably, all of Prof. Tzoulis' clinical research is academically-driven and based largely on public funding.
About the study
Dr. Tzoulis and his team of researchers sought to assess short-term tolerability and impact on NAD+ as well as clinical severity of PD. Exploratory outcomes included changes in serum homocysteine levels, fasting blood glucose, and serum insulin levels.
The study was a randomized, double-blind, placebo-controlled, phase I clinical trial in 20 individuals with idiopathic PD fulfilling the criteria set by the Movement Disorders Society (MDS). Individuals with PD were given 3,000 mg of NR per day or placebo for four consecutive weeks. They were assessed based on clinical and molecular measures, an electrocardiogram, and through the MDS-UPDRS rating scale, a tool used by medical professionals and researchers to assess and measure the severity of PD symptoms.
Study highlights
<ul>
<li>High-dose NR was safe and well-tolerated with no related adverse events.</li>
<li>NR significantly increased NAD+ levels and modified the NAD+ metabolome in whole blood.</li>
<li>High-dose NR did not alter whole blood homocysteine, or other major methyl donor groups, suggesting no impact on methyl donor group pool.</li>
<li>NR was associated with a significant improvement of clinical symptoms of PD, measured by MDS-UPDRS, suggesting augmenting NAD+ levels may have a symptomatic anti-Parkinson's effect.</li>
</ul>
Relevance
This promising milestone research demonstrates that high-dose NR at 3,000 mg per day is safe, well-tolerated, and may improve clinical symptoms for PD. These results set the stage for the long-term NO-PARK Phase II/III clinical study, which will determine if NR can delay disease progression in persons with PD. Further, Prof. Tzoulis and his team of investigators are conducting the N-DOSE clinical trial to determine the optimal safe dose to assess the efficacy of NR as part of the treatment of PD (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05589766&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=7&amp;md5=ef18980cb89b8eeaf9e78b6522da4d31">clinicaltrials.gov</a>).
For additional information on the science supporting Niagen&#xAE; visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.chromadex.com&amp;esheet=53864526&amp;newsitemid=20231130509791&amp;lan=en-US&amp;anchor=www.chromadex.com&amp;index=8&amp;md5=e6d4896f48ba32e2749e6d55ca62d95b">www.chromadex.com</a>.

Biotech

General

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside, Supplementation Induces A Potent NAD+ Response And Is Associated With Mild Improvement In Parkinson's Disease